Erlotinib Completed Phase 0 Trials for Pharynx Cancer / Head and Neck Carcinoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment0
clinicaltrials.gov IdentifierTitleDrugs
NCT00140556Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer
NCT00601913Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery